3,485 press releases in English indexed under healthcare.
This milestone brings complex cardiothoracic surgical care closer to home for patients in Hernando County and surrounding communities, backed by the expertise and resources of Tampa General's academic health system. TAMPA, Fla., Aug. 24, 2026 -- Tampa General Hospital (TGH)...
YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
NEW YORK, Aug. 24, 2026 -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more...
NEW YORK, Aug. 24, 2026 -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) securities between January 13, 2025 through January 29, 2026,, inclusive (the “Class Period”).
San Diego, California--(August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company...
New York, NY – August 24, 2026 – In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National […]
LYON, France, August 24, 2026--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the "Company") a clinical-stage biopharmaceutical company focused on the research and development of i
ATLANTA, Aug. 24, 2026 -- A shareholder class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl”) (NASDAQ: GUTS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy.
“AI is helping functional nutrition become more personalized, science-driven and responsive to changing consumer health needs.”
RADNOR, Pa., Aug. 24, 2026 -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who...
Company announcement – No. 42 / 2026
Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical...